Fetal therapy of severe symptomatic @entity3252 using XXXX .

@entity1 @entity72696 @entity4766 @entity1276 @entity1283 @entity843 @entity9230 @entity4580 @entity693 @entity828 @entity6519 @entity299 @entity3252 @entity3251 @entity4765 @entity2241 @entity3204
Severe symptomatic @entity3251 rarely occurs after the maternal primary infection of @entity3204 . We herein report our experience of fetal therapy of symptomatic @entity3252 using @entity4580 . Ultrasound assessment at 23 weeks' gestation revealed @entity2241 , @entity299 , @entity1283 , enlarged lateral ventricles and thickened placenta. Serum @entity3204 gondii antibody titer was  81,920. @entity3204 immunoglobulin M was 2.4 index (normal, <0.8 index), and immunoglobulin G was >= 240 IU/mL (normal, <6 IU/mL). Maternal oral administration of @entity4580 in addition to @entity9230 , @entity4765 and @entity72696 was conducted. Spontaneous vaginal delivery occurred at 32 weeks and a male @entity1 weighing 2036 g was born. @entity828 , @entity6519 , @entity1276 , intracranial calcifications, @entity843 , and @entity693 were confirmed after birth. The @entity1 underwent therapy with @entity4765 and @entity4766 . It seems imperative to establish a new drug choice for fetal therapy of severe symptomatic @entity3252 in order to reduce the maternal and fetal risks of drug side-effects.
